Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

'All systems go' with ReNeuron Group Plc looking to treat first PISCES III patient shortly

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE), tells Proactive's Andrew Scott a Phase IIb clinical trial of their potentially breakthrough CTX cell treatment for stroke will soon get underway in the US.

The first of a group of 110 patients taking part in PISCES III will be enrolled ‘shortly’.

Top-line data from the randomised, placebo-controlled study is expected in early 2020, having been previously penciled in for the end of 2019.

 
Meet Anglo Asian Mining PLC, Jersey Oil and Gas PLC, Europa Oil & Gas (Holdings) Plc, ANGLE plc and Eurasia Mining plc at our event, Dublin , 22 November 2018. Register here »
View full RENE profile View Profile

ReNeuron Group Plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use